Pharma’s Almanac Article Featuring Ronawk
Changing the Future of Cell Culture and Accelerating Next-Generation Therapies
Ronawk has developed a new 3D solution that enables the easy growth of large quantities of cells of a consistent phenotype. The company’s CEO and Founder A.J. Mellott, Ph.D., and Chief Revenue Officer Scott Leigh discuss the potential applications for the technology and their hopes for enabling significant advances in pharma manufacturing and beyond with Pharma’s Almanac Editor in Chief David Alvaro, Ph.D.
by David Alvaro
The Ronawk team takes some time to talk with Pharma’s Almanac Editor and Chief, David Alvaro, about the start of the company, the Bio-Block technology, and how the company plan to innovate cell culture using 3D cell culture.
“The eureka moment was when I had a very simple thought: Why can’t we grow cells in 3D from the beginning? When cells start growing in the body, they’re really growing in 3D. Nothing in the body — tissues and organs, etc. — is flat or 2D. It’s all contoured. If we could grow cells in a 3D format from the beginning, maybe we could we get higher-quality cells and create more accurate models.
The answer to the question was yes, but that then led to other questions, such as whether cells grown in a 3D format can expand, how nutrient diffusion and gas exchange could be handled, and so on, in order to provide an environment that closely mimics the original, natural cell environment.” – AJ Mellott, CEO